Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Eton Pharmaceuticals Inc(ETON)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ETON
10/20/2026: ETON (3-star) is currently NOT-A-BUY. Pass it for now.
Eton Pharmaceuticals is a specialized biopharmaceutical company focused on developing and marketing treatments for rare diseases and hospital-based clinical needs. Its core strength lies in a lean operational model that identifies high-value, niche pharmaceutical assets for acquisition or development, allowing for efficient commercialization. The main growth story hinges on expanding its rare disease portfolio and successfully navigating FDA pathways for new orphan drug indications. However, risks include concentration in a limited product portfolio, intense competition from larger firms, and potential pricing headwinds. The stock may suit growth-oriented investors interested in small-cap biotech, though it lacks dividend income and carries the volatility typical of clinical-stage development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active growth phase, focusing on expanding its commercial product portfolio. |
| Momentum investor | Mixed fit | Momentum depends on the success of regulatory filings and product launches which are inherently volatile. |
| Value investor | Weak fit | Eton is currently focused on capital-intensive growth rather than yielding value through traditional metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all cash for reinvestment. |
| Low-risk investor | Weak fit | The company's reliance on a small number of products creates significant risk profile concerns. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks are subject to significant swings based on clinical and regulatory outcomes. |
| Valuation risk | Medium / high | Valuations are often based on future growth prospects rather than current cash flow generation. |
| Competition risk (specialty pharma) | Medium | Eton faces competition from both generic entrants and larger biotech companies. |
| Business quality | Medium | The company is still proving the sustainability and scalability of its specialty business model. |
| Dividend income | Low / none | The company reinvests all capital and does not offer income to shareholders. |
| Execution risk | Medium / high | The success of the firm depends heavily on navigating complex FDA processes and scaling commercial teams. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 570.28% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/20/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio 123.05 | 1Y Target Price 71.5 |
Price to earnings Ratio 123.05 | 1Y Target Price 71.5 | ||
Volume (30-day avg) 551.3K shares | Beta 0.9 | 52 Weeks Range 14.27 - 66.37 | Updated Date 10/19/2026 |
52 Weeks Range 14.27 - 66.37 | Updated Date 10/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Rare Disease Portfolio | Revenue from sales of specialized treatments for orphan indications. | This is the primary revenue driver, focusing on high-margin treatments for small patient populations. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 123.05 | Forward PE 23.92 | Enterprise Value 1.59B | Price to Sales(TTM) 13.32 |
Enterprise Value 1.59B | Price to Sales(TTM) 13.32 | ||
Enterprise Value to Revenue 15.08 | Enterprise Value to EBITDA 76.37 | Shares Outstanding 28.58M | Shares Floating 22.30M |
Shares Outstanding 28.58M | Shares Floating 22.30M | ||
Percent Insiders 4.89 | Percent Institutions 71.32 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.